Tafsiri hii bado inaandaliwa. Kwa sasa tunaonyesha kwa muda toleo asili la Kiingereza.
Kampuni changa · 27/10/20261 min read
Orphan Therapeutics Accelerator In-Licenses Investigational Gene Therapy Program for Ornithine Transcarbamylase Deficiency from UCL Ventures and Children's Medical Research Institute
Tafsiri ya kiotomatiki ya ndani · Lugha asili ya chanzo
Muhtasari
OTXL-101, a promising therapy in development for a severe, rare pediatric metabolic condition, becomes the first pipeline program to be in-licensed by Orphan Therapeutics Accelerator (OTXL) CAMBRIDGE, Mass., Oct. 27,…
Lugha asili ya chanzo: PR Newswire UK — News ReleasesFungua taarifa asili →